Top News : Yamana Gold(NYSE:AUY), Yingli Green Energy Holding Co. (NYSE:YGE), Regulus Therapeutics Inc. (NASDAQ:RGLS), Novavax(NASDAQ:NVAX), Nucor (NYSE:NUE)


Yamana Gold Inc. (NYSE:AUY) will release its third quarter 2014 results after market close on October 29, 2014 followed by a conference call and webcast on October 30, 2014 at 8:30 a.m. ET. Yamana Gold, Inc. (NYSE:AUY) in last trading activity fell -2.14% to close at $5.50. Company weekly performance is -3.34% while its quarterly performance stands at -34.21%. Yamana Gold, Inc. (NYSE:AUY) is -47.90% away from its 52 week high.

Yingli Green Energy Holding Co. Ltd. (NYSE:YGE) announced that the Company has successfully completed its fifth annual global investor day in Las Vegas, Nevada, USA, on Tuesday, October 21 st, 2014. On last trading day Yingli Green Energy Holding Co. Ltd. (NYSE:YGE) fell -3.42% to close at $2.82. Its volatility for the week is 5.59% while volatility for the month is 6.81%. YGE’s sales growth for past 5 years was 12.20% and its EPS growth for past 5 years was -34.90%. Yingli Green Energy Holding Co. Ltd. (NYSE:YGE) monthly performance is -16.57%.

Regulus Therapeutics Inc. (NASDAQ:RGLS) announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell approximately $80,000,000 of shares of its common stock, of which approximately $70,000,000 of shares are being offered by Regulus and approximately $10,000,000 of shares are being offered by an existing stockholder of Regulus, Isis Pharmaceuticals, Inc. On last trading day Regulus Therapeutics Inc. (NASDAQ:RGLS) advanced 6.58% to close at $18.47. Its volatility for the week is 23.78% while volatility for the month is 10.51%. Regulus Therapeutics Inc. (NASDAQ:RGLS) monthly performance is 159.05%.

Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced that Gregory Glenn, M.D., SVP, Research and Development is presenting new immunogenicity data from Novavax’ RSV F-Protein Nanoparticle vaccine candidate (RSV F vaccine) clinical trials at the 8th Vaccine & ISV Congress in Philadelphia, PA. Novavax, Inc. (NASDAQ:NVAX) has 0.10% insider ownership while its institutional ownership stands at 58.60%. In last trading activity company’s stock closed at $5.80.

Nucor Corporation (NYSE:NUE) was upgraded by equities research analysts at Credit Agricole from an “underperform” rating to an “outperform” rating in a research note issued to investors on Friday, TheFlyOnTheWall.com reports. On Monday shares of Nucor Corporation (NYSE:NUE) closed at $52.20. Company’s sales growth for last 5 years was -4.20% and EPS growth for next 5 years is recorded as 39.69%.


Leave a Reply

Your email address will not be published. Required fields are marked *